Call us : USA : 1-631-381-2994; Europe : 44-207-097-1828
Mail us : info@creative-biolabs.com
Creative Biolabs Bispecific Antibody Blog

Menu

Skip to content
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News

Monthly Archives: March 2019

TG Therapeutics’s new anti-CD47 and CD19 therapy TG-1801 enters Phase I clinical practice

March 2, 2019Bispecific Antibody Clinic, Bispecific Antibody Research, NewsbsAb, CD19-CD47biobsab

TG Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for patients with B-cell-mediated diseases. Recently, the company announced the launch of TG-1801 ‘s first human Phase I study, a new,Read More…

Categories

  • Bispecific Antibody Clinic
  • Bispecific Antibody Research
  • News

Recent Posts

  • Bispecific Antibodies Targeting Dual Tumor-associated Antigens
  • Difficulties and Prospects in the Research and Development of Bispecific Antibodies
  • Current Status of Research and Development of Multispecific Antibodies
  • How to Develop A Qualified Bispecific Antibody
  • Amgen Bispecific Antibody BLINCYTO® (blinatumomab) Significantly Prolongs the Overall Survival Time of Patients with Leukemia

Archives

  • December 2020
  • October 2020
  • August 2020
  • June 2019
  • April 2019
  • March 2019
  • February 2019
  • December 2018
  • November 2018
  • October 2018

Contact Us

USA:
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: info@creative-biolabs.com
Europe:
Tel: 44-207-097-1828
Copyright © Creative Biolabs Bispecific Antibody Blog
Powered by WordPress , Designed and Developed by templatesnext
MENU
  • Bispecific Antibody Research
  • Bispecific Antibody Clinic
  • News